SI
EW icon

Sofinnova Investments’s Edwards Lifesciences EW Stock Holding History

Sofinnova Investments’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500,000
Closed -$46.2M – 72
2024
Q2 		$46.2M Buy
+500,000
New +$44.3M 2.4% 11

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sofinnova Investments's EW Position: Q1 2025 in Review

Sofinnova Investments sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 40,000 shares — an estimated $2.96M sold.

Sofinnova Investments first reported a position in EW in Q4 2021 and held it in 5 quarters. The position peaked at $66.9M in Q2 2024. 1,204 funds tracked by Wall St. Rank hold EW as of Q1 2025.

  • Sofinnova Investments reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
  • Sofinnova Investments sold 40,000 Edwards Lifesciences shares in Q1 2025, an estimated $2.96M.
  • Sofinnova Investments first reported a position in Edwards Lifesciences in Q4 2021 and held it in 5 quarters.
  • Sofinnova Investments's Edwards Lifesciences position peaked at $66.9M in Q2 2024.
  • 1,204 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.